23andMe has secured FDA approval to begin commercialization of Personal Genome Service Genetic Health Risk tests for ten disease conditions. The test will be marketed as a direct-to-consumer genetic risk assessment, allowing users to determine genetic risk information for certain disease conditions in the comfort of their own homes. Test results may be used by patients to have informed discussions with their physicians and determine lifestyle choices. Read the full press release here.